When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BHVN - Biohaven on go with study of vazegepant in COVID-19 as others take action amid the pandemic
Biohaven Pharmaceutical Holding Company Ltd.
The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE:BHVN) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who need supplemental oxygen. Shares up 4% premarket.
More news on: Biohaven Pharmaceutical Holding Company Ltd., Otonomy, Inc., Laboratory Corporation of America Holdings, Healthcare stocks news, Stocks on the move,